CryoLife Inc. (NYSE:CRY) shares reached a new 52-week high on Monday . The company traded as high as $16.27 and last traded at $16.20, with a volume of 242,478 shares. The stock had previously closed at $15.67.

A number of research firms recently weighed in on CRY. Canaccord Genuity reissued a “buy” rating on shares of CryoLife in a report on Tuesday, July 26th. Zacks Investment Research lowered CryoLife from a “buy” rating to a “hold” rating in a report on Wednesday, July 27th. Piper Jaffray Cos. reaffirmed an “overweight” rating and issued a $16.00 price objective on shares of CryoLife in a report on Wednesday, July 27th. Finally, Lake Street Capital assumed coverage on CryoLife in a report on Wednesday, June 15th. They issued a “buy” rating and a $15.00 price objective on the stock. One research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $15.00.

The stock has a 50 day moving average of $13.99 and a 200-day moving average of $12.03. The company has a market cap of $557.36 million and a P/E ratio of 52.37.

CryoLife (NYSE:CRY) last issued its quarterly earnings results on Monday, July 25th. The company reported $0.13 EPS for the quarter, topping the Zacks’ consensus estimate of $0.02 by $0.11. The business had revenue of $47.10 million for the quarter, compared to the consensus estimate of $35.50 million. The business’s revenue was up 32.6% compared to the same quarter last year. During the same quarter last year, the business posted $0.03 earnings per share. On average, equities research analysts anticipate that CryoLife Inc. will post $0.24 earnings per share for the current year.

In related news, Director Ronald D. Mccall sold 10,000 shares of CryoLife stock in a transaction on Wednesday, June 1st. The stock was sold at an average price of $11.56, for a total transaction of $115,600.00. Following the sale, the director now directly owns 156,248 shares in the company, valued at $1,806,226.88. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director C Elkins Ronald sold 2,000 shares of CryoLife stock in a transaction on Tuesday, July 26th. The stock was sold at an average price of $14.00, for a total value of $28,000.00. Following the sale, the director now owns 103,586 shares in the company, valued at $1,450,204. The disclosure for this sale can be found here.

An institutional investor recently raised its position in CryoLife stock. Morgan Stanley raised its position in CryoLife Inc. (NYSE:CRY) by 1.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,605,563 shares of the company’s stock after buying an additional 21,067 shares during the period. Morgan Stanley owned 5.64% of CryoLife worth $17,308,000 at the end of the most recent reporting period.

CryoLife, Inc (CryoLife) is engaged in medical device manufacturing and distribution, and in the processing and distribution of implantable human tissues for cardiac and vascular surgeries. The Company operates in two segments: Medical Devices and Preservation Services. The Medical Devices segment sells BioGlue, BioFoam, PerClot, CardioGenesis cardiac laser therapy, Hemodialysis Reliable Outflow (HeRO) Graft, and ProCol Vascular Bioprosthesis (ProCol).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.